Using the polymeric circulating tumor cell chip to capture circulating tumor cells in blood samples of patients with colorectal cancer
Using the polymeric circulating tumor cell chip to capture circulating tumor cells in blood samples of patients with colorectal cancer
复制标题
DOI：
10.3892/ol.2020.11335
复制
发表时间：
2020-03-01
期刊：
影响因子：
2.9
通讯作者：
Komiyama, Hiromitsu
中科院分区：
文献类型：
--
作者：
Kure, Kazumasa;Hosoya, Masaki;Komiyama, Hiromitsu
目前的研究阐明了循环肿瘤细胞(CTC)检测系统使用血液样本诊断结直肠癌的准确性。该系统使用了用于CTC分离的微流控装置--聚合CTC芯片(CTC芯片)。CTC被认为是敏感的诊断生物标志物。然而，它们在外周血液中的浓度很低，需要高度敏感和特定的捕获技术。首先使用结直肠癌细胞系HCT-116的细胞悬液来评估聚合物CTC芯片的捕获效率，据报道，在磷酸盐缓冲盐水悬液中的细胞悬液中的捕获效率为90.9%，在血液中的捕获效率为65.0%。然后用CTC芯片检测了13例II-IV期结直肠癌患者的血液样本中的CTC。平均而言，II期和III期结直肠癌患者的CTCs/ml(3.3+/-2.3)低于IV期患者(7.0+/-6.2)。在II-IV期患者中，92%的患者>；=1 CTC/ml，显著高于糖类抗原19-9试验(CA19-9)检测的阳性率(15%)。此外，在所有II期和III期结直肠癌患者中都检测到了CTC，包括一些癌胚抗原(CEA)和CA19-9试验阴性的患者。利用聚合CTC芯片检测系统，CTC可以成为有效的癌症标记物，特别是对于常规血清标记物检测结果经常为阴性的II和III期结直肠癌患者。CTC芯片系统还可以促进基于CTC浓度的癌症进展的检测。
The current study clarified the accuracy of a circulating tumor cell (CTC) detection system to diagnose colorectal cancer using blood samples. The system uses the 'polymeric CTC-chip,' (CTC-chip), which is a microfluidic device that is used for CTC isolation. CTCs are considered sensitive diagnostic biomarkers. However, their concentration in the peripheral blood is low and requires highly sensitive and specific capturing techniques. The capture efficiency of the polymeric CTC-chip was first assessed using cell suspensions of the colorectal cancer cell line HCT-116, which was reported as 90.9% in a phosphate-buffered saline suspension and 65.0% in the blood. The CTC-chip was then used to detect CTCs in blood samples obtained from 13 patients with stage II-IV colorectal cancer. On average, the CTCs/ml was lower in patients with stages II and III colorectal cancer (3.3 +/- 2.3) than in those with stage IV (7.0 +/- 6.2). In patients with stages II-IV, 92% had >= 1 CTC per ml, which was significantly higher than the positive rate (15%) detected using the carbohydrate antigen 19-9 test (CA19-9). Furthermore, CTCs were detected in all patients with stage II and III colorectal cancer, including a number of patients with negative results for the carcinoembryonic antigen (CEA) and CA19-9 tests. With the polymeric CTC-chip detection system, CTCs can be effective cancer markers, particularly for patients with stage II and III colorectal cancer who often exhibit negative conventional serum marker test results. The CTC-chip system may also facilitate the detection of cancer progression based on CTC concentration.